NeoGenomics, Inc. (NASDAQ: NEO) Advances RaDaR® Technology and Resolves Litigation with Natera

2 min read | September 23, 2024 09:51 PM PDT | By Team Kalkine Media

Google News:

NeoGenomics, Inc. (NASDAQ: NEO) Advances RaDaR® Technology and Resolves Litigation with Natera — Image source: Shutterstock

Recent News

Coca-Cola Stock (NYSE:KO) Valuation After Strong Long-Term Returns

Trane Technologies (NYSE:TT) Draws Fresh ESG Spotlight

Phillips 66 (NYSE:PSX) Valuation Buzz Turns Energy Eyes Sharper

Lowe’s Companies (NYSE:LOW) Brand Push Gets Louder

Make Kalkine Media
My Trusted Source

NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, has announced significant developments regarding its RaDaR® technology, which is designed to enhance the precision of cancer detection and monitoring. In a statement addressing recent inquiries, NeoGenomics confirmed that it has successfully cleared the feasibility stage with a new iteration of its RaDaR technology and has reached a resolution in its litigation with Natera concerning the earlier version, RaDaR 1.0.

The RaDaR technology, which stands for “Rapid Detection of Residual Disease,” is instrumental in monitoring minimal residual disease (MRD) in cancer patients. This innovative approach aims to provide oncologists with critical insights into the effectiveness of treatments and the potential for disease recurrence. The latest advancements in RaDaR technology represent a key milestone for NeoGenomics, underscoring the company’s commitment to improving patient outcomes through cutting-edge diagnostic solutions.

In light of the accelerated progress with the new RaDaR technology, NeoGenomics was able to negotiate a settlement with Natera regarding the RaDaR 1.0 litigation. While the specifics of the settlement remain confidential, the company has indicated that it is not material to its financial performance. Notably, this resolution does not affect NeoGenomics' adjusted EBITDA guidance range or liquidity expectations, allowing the company to maintain its financial stability as it continues to innovate in the oncology testing space.

To further discuss these developments, NeoGenomics will host a business update conference call and webcast on Tuesday, September 24, 2024, starting at 8:30 a.m. Eastern Time. This call is expected to provide investors and stakeholders with detailed insights into the company’s strategic direction, recent achievements, and future plans, particularly concerning the new RaDaR technology and its potential impact on the oncology testing market.

NeoGenomics has consistently positioned itself as a frontrunner in the oncology testing sector, focusing on delivering high-quality, comprehensive testing services that meet the evolving needs of healthcare providers and patients. The resolution of the litigation with Natera allows the company to refocus its efforts on innovation and market expansion without the distraction of ongoing legal challenges.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.